Cumberland announced the launch of Caldolor (ibuprofen) injection for the treatment of pain and fever in children aged ≥6 months. 

Caldolor injection is intended mainly for hospitalized patients who have intolerable pain or cannot take oral fever medications. It is the first non-steroidal anti-inflammatory drug (NSAID) injectable approved for this pediatric indication. 

Caldolor injection gained approval from the Food and Drug Administration (FDA) in November 2015 for this pediatric indication. It is also indicated in adults and children for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever.  

RELATED: Caldolor Approved to Manage Pediatric Pain, Fever

Caldolor possesses analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of CALDOLOR, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2).

Caldolor is available as a 800mg/8mL (100mg/mL) solution for intravenous (IV) use single-dose vials in 25-count cartons.

For more information call (877) 484-2700 or visit